Albireo completes A3309 phase 1b study in patients with chronic idiopathic constipation

Nov 18 2009NewsGuard 100/100 Score

Albireo today announced the completion of a phase 1b study showing a favorable tolerability and safety profile of A3309 in patients with chronic idiopathic constipation. In addition, the data revealed appropriate efficacy signals in this patient population.

A3309 is a first in class compound developed for the treatment of chronic idiopathic constipation and constipation-predominant Irritable Bowel Syndrome (IBS-C). Based on these results, Albireo expects to recruit 180 patients with chronic idiopathic constipation in a US phase 2b study (http://www.clinicaltrials.gov) under an IND recently placed into effect by the FDA.

Source:

Albireo

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , ,

Comments (0)

Suggested Reading

Ozempic effective for patients with chronic kidney damage
Chronic cough can be passed down from parents to children, a new study suggests
Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options
Brazil nuts reduce inflammation and improve gut health in women on restricted diets
Chronic Urticaria: Addressing unmet needs, emerging therapies, and advances in personalized treatment approaches
AI reveals genetic links in aging, chronic diseases, and lifestyle factors across nine organ systems
Researchers reveal why a diet rich in magnesium is so important for your health
Neurodivergent children face higher risk of chronic disabling fatigue by 18, study finds

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
How gut microbiome and fiber diversity shape chronic disease outcomes